A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
Status:
Completed
Trial end date:
2020-06-25
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus
atezolizumab in participants with advanced solid tumors including the following cohorts:
squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), and renal
cell carcinoma (RCC).